Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems
- 1 July 2003
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 55 (7) , 895-902
- https://doi.org/10.1211/0022357021341
Abstract
The feasibility of applying biodegradable polybutylcyanoacrylate (PBCA) nanoparticulate delivery systems (NDSs) for the controlled release of paclitaxel was investigated. Paclitaxel-loaded and unloaded PBCA-NDSs containing various surfactants (dextran 70, cholesterol, polyvinyl alcohol and lecithin) were prepared by anionic polymerization. The effects of surfactant (1% w/v), surfactant combination (1% w/v each), and surfactant concentration (0.05, 1.0 and 2.5% w/v) on PBCA-NDSs were evaluated and characterized by particle size, zeta potential, entrapment efficiency, and in-vitro paclitaxel release kinetics. The physicochemical characteristics of PBCA-NDSs incorporated with various surfactants were significantly improved compared with PBCA-NDS without any surfactant, by decreasing particle size at least 3-fold as well as by increasing the zeta potential up to 18-fold to minimize the agglomeration of nanoparticles. Moreover, PBCA-NDSs incorporated with various surfactants demonstrated higher entrapment efficiency of paclitaxel. Results from the in-vitro release kinetic studies indicated that a more controlled biphasic zero-order release pattern of paclitaxel was observed for PBCA-NDSs incorporated with various surfactants. Compared with dextran 70 and polyvinyl alcohol, the naturally occurring lipids, lecithin and cholesterol, indicated greater advantages in improving the physicochemical properties of PBCA-NDSs, in terms of smaller particle size, higher zeta potential and better drug entrapment efficiency, and better controlled release of paclitaxel, in terms of lower release rate and prolonged action from PBCA-NDSs.Keywords
This publication has 24 references indexed in Scilit:
- Poly(ethylene glycol)–human serum albumin–paclitaxel conjugates: preparation, characterization and pharmacokineticsJournal of Controlled Release, 2001
- Polymer–drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinicJournal of Controlled Release, 2001
- Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymersJournal of Controlled Release, 2001
- Defining the drug incorporation properties of PLA–PEG nanoparticlesInternational Journal of Pharmaceutics, 2000
- Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxelJournal of Controlled Release, 2000
- Physico-chemical characterization of insulin-loaded poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerizationInternational Journal of Pharmaceutics, 1999
- Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery systemJournal of Controlled Release, 1999
- Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymer matrixJournal of Controlled Release, 1999
- Mechanism of action of taxolTrends in Pharmacological Sciences, 1992
- Particle size and size distribution of poly(butyl 2-cyanoacrylate) nanoparticles. II. Influence of stabilizersJournal of Colloid and Interface Science, 1985